Forget SpaceX: Invest in Weight Loss Drugs, Says Guru

SpaceX's recent $75 billion IPO, the largest on record, has already seen its shares decline, drawing criticism from entrepreneur Scott Galloway. He argues the IPO was manipulated to inflate the stock price, suggesting it's a 'trade' driven by forced index fund purchases rather than inherent value. Galloway recommends investors shift their focus to GLP-1 drugs, a class of medications initially approved for weight loss that now show potential across a wide range of conditions including obesity, addiction, and cancer.

Eli Lilly is positioned as a frontrunner in the GLP-1 market, with its stock experiencing a significant surge of 418% since 2021. The company is actively developing new combination GLP-1 drugs showing promising trial results, which could further boost its stock value. While competitors like Novo Nordisk have also entered the market, Eli Lilly's direct-to-consumer marketing strategies appear more effective. The high cost of GLP-1s remains a significant barrier, with monthly expenses in the hundreds of dollars, though Eli Lilly has initiated programs to make the drugs more accessible to seniors and uninsured individuals.